Recent Developments in Peptidyl Diaryl Phoshonates As Inhibitors and Activity-Based Probes for Serine Proteases

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2019 Jun 13

PMID 31185654

Citations 5

Authors

Marta Maslanka

Artur Mucha

Affiliations

Soon will be listed here.

Abstract

This review presents current achievements in peptidyl diaryl phosphonates as covalent, specific mechanism-based inhibitors of serine proteases. Along three decades diaryl phosphonates have emerged as invaluable tools in fundamental and applicative studies involving these hydrolases. Such an impact has been promoted by advantageous features that characterize the phosphonate compounds and their use. First, the synthesis is versatile and allows comprehensive structural modification and diversification. Accordingly, reactivity and specificity of these bioactive molecules can be easily controlled by appropriate adjustments of the side chains and the leaving groups. Secondly, the phosphonates target exclusively serine proteases and leave other oxygen and sulfur nucleophiles intact. Synthetic accessibility, lack of toxicity, and promising pharmacokinetic properties make them good drug candidates. In consequence, the utility of peptidyl diaryl phosphonates continuously increases and involves novel enzymatic targets and innovative aspects of application. For example, conjugation of the structures of specific inhibitors with reporter groups has become a convenient approach to construct activity-based molecular probes capable of monitoring location and distribution of serine proteases.

Citing Articles

Site-Selective Incorporation of a Functional Group into Lys175 in the Vicinity of the Active Site of Chymotrypsin by Using Peptidyl α-Aminoalkylphosphonate Diphenyl Ester-Derivatives.

Ono S, Koga M, Arimura Y, Hatakeyama T, Kobayashi M, Sagara J Molecules. 2023; 28(7).

PMID: 37049913 PMC: 10096113. DOI: 10.3390/molecules28073150.

Novel inhibitors and activity-based probes targeting serine proteases.

Ferguson T, Reihill J, Martin S, Walker B Front Chem. 2022; 10:1006618.

PMID: 36247662 PMC: 9555310. DOI: 10.3389/fchem.2022.1006618.

Phosphonopeptides containing free phosphonic groups: recent advances.

Kafarski P RSC Adv. 2022; 10(43):25898-25910.

PMID: 35518575 PMC: 9055344. DOI: 10.1039/d0ra04655h.

Hybrid Quinolinyl Phosphonates as Heterocyclic Carboxylate Isosteres: Synthesis and Biological Evaluation against Topoisomerase 1B (TOP1B).

Selas A, Fuertes M, Melcon-Fernandez E, Perez-Pertejo Y, Reguera R, Balana-Fouce R Pharmaceuticals (Basel). 2021; 14(8).

PMID: 34451880 PMC: 8399847. DOI: 10.3390/ph14080784.

A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer.

Lovell S, Zhang L, Kryza T, Neodo A, Bock N, De Vita E J Am Chem Soc. 2021; 143(23):8911-8924.

PMID: 34085829 PMC: 9282638. DOI: 10.1021/jacs.1c03950.

References

Walker B, Wharry S, Hamilton R, Martin S, Healy A, Walker B . Asymmetric preference of serine proteases toward phosphonate and phosphinate esters. Biochem Biophys Res Commun. 2000; 276(3):1235-9. DOI: 10.1006/bbrc.2000.3597. View

Augustyns K, Van der Veken P, Senten K, Haemers A . The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases. Curr Med Chem. 2005; 12(8):971-98. DOI: 10.2174/0929867053507298. View

Sienczyk M, Oleksyszyn J . Inhibition of trypsin and urokinase by Cbz-amino(4-guanidinophenyl)methanephosphonate aromatic ester derivatives: the influence of the ester group on their biological activity. Bioorg Med Chem Lett. 2006; 16(11):2886-90. DOI: 10.1016/j.bmcl.2006.03.002. View

Pan Z, Jeffery D, Chehade K, Beltman J, Clark J, Grothaus P . Development of activity-based probes for trypsin-family serine proteases. Bioorg Med Chem Lett. 2006; 16(11):2882-5. DOI: 10.1016/j.bmcl.2006.03.012. View

Lin C, Kwong A, Perni R . Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect Disord Drug Targets. 2006; 6(1):3-16. DOI: 10.2174/187152606776056706. View

Venkatraman S, Bogen S, Arasappan A, Bennett F, Chen K, Jao E . Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally.... J Med Chem. 2006; 49(20):6074-86. DOI: 10.1021/jm060325b. View

Sienczyk M, Oleksyszyn J . Irreversible inhibition of serine proteases - design and in vivo activity of diaryl alpha-aminophosphonate derivatives. Curr Med Chem. 2009; 16(13):1673-87. DOI: 10.2174/092986709788186246. View

Gilmore B, Quinn D, Duff T, Cathcart G, Scott C, Walker B . Expedited solid-phase synthesis of fluorescently labeled and biotinylated aminoalkane diphenyl phosphonate affinity probes for chymotrypsin- and elastase-like serine proteases. Bioconjug Chem. 2009; 20(11):2098-105. DOI: 10.1021/bc9002162. View

Oleksyszyn J, POWERS J . Irreversible inhibition of serine proteases by peptide derivatives of (alpha-aminoalkyl)phosphonate diphenyl esters. Biochemistry. 1991; 30(2):485-93. DOI: 10.1021/bi00216a026. View

10.

Sabido E, Tarrago T, Giralt E . Towards the identification of unknown neuropeptide precursor-processing enzymes: Design and synthesis of a new family of dipeptidyl phosphonate activity probes for substrate-based protease identification. Bioorg Med Chem. 2010; 18(23):8350-5. DOI: 10.1016/j.bmc.2010.09.066. View

11.

Korkmaz B, Horwitz M, Jenne D, Gauthier F . Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev. 2010; 62(4):726-59. PMC: 2993259. DOI: 10.1124/pr.110.002733. View

12.

Morikawa K, Lange C, Gouttenoire J, Meylan E, Brass V, Penin F . Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus. J Viral Hepat. 2011; 18(5):305-15. DOI: 10.1111/j.1365-2893.2011.01451.x. View

13.

Zou F, Schmon M, Sienczyk M, Grzywa R, Palesch D, Boehm B . Application of a novel highly sensitive activity-based probe for detection of cathepsin G. Anal Biochem. 2011; 421(2):667-72. DOI: 10.1016/j.ab.2011.11.016. View

14.

Perera N, Schilling O, Kittel H, Back W, Kremmer E, Jenne D . NSP4, an elastase-related protease in human neutrophils with arginine specificity. Proc Natl Acad Sci U S A. 2012; 109(16):6229-34. PMC: 3341072. DOI: 10.1073/pnas.1200470109. View

15.

Winiarski L, Oleksyszyn J, Sienczyk M . Human neutrophil elastase phosphonic inhibitors with improved potency of action. J Med Chem. 2012; 55(14):6541-53. DOI: 10.1021/jm300599x. View

16.

Ewa B, Maciej W, Marcin S, Grzegorz D, Michal Z, Jan P . The development of first Staphylococcus aureus SplB protease inhibitors: phosphonic analogues of glutamine. Bioorg Med Chem Lett. 2012; 22(17):5574-8. DOI: 10.1016/j.bmcl.2012.07.011. View

17.

Grzywa R, Sienczyk M . Phosphonic esters and their application of protease control. Curr Pharm Des. 2012; 19(6):1154-78. DOI: 10.2174/1381612811319060014. View

18.

Skorenski M, Sienczyk M . Viral proteases as targets for drug design. Curr Pharm Des. 2012; 19(6):1126-53. DOI: 10.2174/1381612811319060013. View

19.

Raju R, Goldberg A, Rubin E . Bacterial proteolytic complexes as therapeutic targets. Nat Rev Drug Discov. 2012; 11(10):777-89. DOI: 10.1038/nrd3846. View

20.

Burchacka E, Skorenski M, Sienczyk M, Oleksyszyn J . Phosphonic analogues of glutamic acid as irreversible inhibitors of Staphylococcus aureus endoproteinase GluC: an efficient synthesis and inhibition of the human IgG degradation. Bioorg Med Chem Lett. 2013; 23(5):1412-5. DOI: 10.1016/j.bmcl.2012.12.074. View